Comparative Pharmacology
Head-to-head clinical analysis: JUNIOR STRENGTH MOTRIN versus MOTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNIOR STRENGTH MOTRIN versus MOTRIN.
JUNIOR STRENGTH MOTRIN vs MOTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Non-selective COX-1 and COX-2 inhibitor, reducing prostaglandin synthesis.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
Ibuprofen (Motrin) 200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day for acute pain, and 2400 mg/day for chronic use.
None Documented
None Documented
1.5-2 hours in children; prolonged in neonates (up to 30 hours) and renal impairment. Clinical: short half-life requires frequent dosing for sustained antipyresis/analgesia.
Terminal elimination half-life approximately 2-4 hours in adults with normal renal function; prolonged in elderly and patients with renal impairment (up to 6-8 hours). No significant accumulation occurs with regular dosing.
Renal excretion of inactive metabolites and conjugates (>90%); less than 10% excreted unchanged. Fecal elimination minor (<5%).
Renal excretion of conjugated metabolites (approximately 70-80% as glucuronide and sulfate conjugates); less than 10% excreted unchanged. Biliary/fecal elimination accounts for about 10-20%.
Category C
Category C
NSAID Analgesic
NSAID Analgesic